Cancer Institute– A national cancer institute
designated cancer center

George A. Fisher Jr.

Back to Profile

Publication Details

  • Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

    Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. J Clin Oncol. 1994; 12 (4): 835-42

    To study the effects of cyclosporine (CsA), a modulator of multidrug resistance (MDR), on the pharmacokinetics and toxicities of doxorubicin.

    PubMedID: 8151326

Stanford Medicine Resources:

Footer Links: